Alzheimer’s: Blood Test Detects p-tau217 Protein for Early Diagnosis

The quest for earlier and more accurate Alzheimer’s disease diagnosis has taken a significant step forward with growing evidence supporting the use of a blood-based biomarker, p-tau217. For years, diagnosing Alzheimer’s relied on invasive and expensive methods like cerebrospinal fluid (CSF) analysis or positron emission tomography (PET) scans. Now, research suggests a simple blood test measuring levels of this specific form of the tau protein could dramatically reduce the risk of misdiagnosis, offering a less burdensome path to understanding cognitive decline.

Understanding Alzheimer’s and the Role of Tau

Alzheimer’s disease is characterized by two hallmark pathological features in the brain: amyloid plaques and neurofibrillary tangles. Amyloid plaques are clumps of a protein called amyloid-beta, while neurofibrillary tangles are formed by the abnormal accumulation of a protein called tau. Tau’s normal function is to stabilize the internal structure of nerve cells. Still, in Alzheimer’s, tau undergoes chemical changes and begins to form these tangles within neurons, disrupting cell function and ultimately leading to cell death. The altered form of tau, specifically p-tau217, is now emerging as a particularly promising biomarker.

Traditionally, identifying these changes required either analyzing CSF – a fluid surrounding the brain and spinal cord – or using PET scans to visualize amyloid plaques. Both methods have limitations. CSF analysis is invasive, requiring a lumbar puncture. PET scans are expensive, not widely available, and involve exposure to radiation. A blood test offers a far more accessible and cost-effective alternative.

Recent Advances in Blood-Based Biomarker Research

A study published in Nature Medicine in April 2025, involving nearly 1,800 participants across four European countries and a primary care cohort in Sweden, demonstrated the high accuracy of plasma p-tau217 in detecting Alzheimer’s disease pathology. The research, which used a fully automated Lumipulse immunoassay, found areas under the receiver operating characteristic curves of 0.93–0.96 when comparing p-tau217 levels to abnormal CSF Aβ42:p-tau181 ratios – a standard measure of Alzheimer’s pathology. In secondary care settings (specialist clinics), the test achieved accuracies of 89–91%, with positive predictive values ranging from 89–95% and negative predictive values from 77–90%. Even in primary care, the accuracy was 85%, with positive and negative predictive values of 82% and 88% respectively.

These findings are particularly encouraging because they suggest the test performs well even in real-world clinical settings, not just in highly controlled research environments. The study also indicated that accuracy wasn’t significantly affected by factors like age (though it was slightly lower in those over 80), chronic kidney disease, diabetes, sex, or APOE genotype – a genetic risk factor for Alzheimer’s.

The FDA’s Landmark Clearance

Building on these research findings, the U.S. Food and Drug Administration (FDA) cleared the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test for marketing in May 2025. This is the first in vitro diagnostic device cleared by the FDA that tests blood to aid in the diagnosis of Alzheimer’s disease. The test measures both p-tau217 and beta-amyloid 1-42 levels in plasma (the liquid component of blood) and calculates the ratio between them. The FDA emphasizes that this test is intended for use in adults aged 55 and older exhibiting signs and symptoms of Alzheimer’s disease, to help detect the presence of amyloid plaques.

What Does This Mean for Patients?

The availability of a blood-based biomarker like p-tau217 has the potential to transform the diagnostic landscape for Alzheimer’s disease. Currently, a diagnosis often relies on a clinical evaluation of symptoms, which can be subjective and may not accurately reflect the underlying pathology. This new test offers a more objective measure, potentially leading to earlier and more accurate diagnoses. Earlier diagnosis is crucial because it allows individuals and their families to plan for the future, access available treatments (though currently, these are primarily focused on managing symptoms), and participate in clinical trials.

However, it’s important to understand that this test is not a definitive diagnosis on its own. The FDA clarifies that the test is intended to *aid* in diagnosis, meaning it should be used in conjunction with other clinical evaluations. A positive result doesn’t automatically mean someone has Alzheimer’s, and a negative result doesn’t necessarily rule it out. Further investigation may be needed to confirm the diagnosis and determine the underlying cause of cognitive symptoms.

Limitations and Future Directions

While the results are promising, it’s crucial to acknowledge the limitations of the current research. The Nature Medicine study, while large, was conducted primarily in European populations. Further research is needed to confirm these findings in more diverse populations and to assess the test’s performance across different ethnic and racial groups. The study also noted that accuracy was slightly lower in participants aged 80 or older, suggesting that age may be a factor to consider when interpreting results.

the test measures amyloid and tau pathology, but these are not the only factors involved in Alzheimer’s disease. Other factors, such as vascular health and inflammation, also play a role. Ongoing research is exploring the potential of combining p-tau217 with other biomarkers to create a more comprehensive diagnostic picture.

What Comes Next: Refining and Expanding Access

The clearance of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test by the FDA is just the first step. Widespread adoption will require ensuring that the test is readily available in clinical laboratories and that healthcare professionals are trained in its proper use, and interpretation. Continued monitoring of the test’s performance in real-world settings will be essential to identify any potential issues and refine its accuracy. Researchers are also exploring the potential of using p-tau217 to monitor the progression of Alzheimer’s disease and to assess the effectiveness of new treatments. Further investigation into the various isoforms of phosphorylated tau is also underway, potentially leading to even more refined biomarkers in the future.